Barely Significant
← all excerpts

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.

Blood Adv · 2022 · PMC8905688 · PMID 34700344

Europe PMCDOI
1
hedged sentence
0.1000
closest p · 2.0× alpha
0.1000
boldest claim

The sentences

did not reach statistical significanceP = .10so close (0.05 < p ≤ 0.1)
In those who finished 6 cycles of combination therapy, there was an improvement in PFS for those that continued IBR over other treatments; however, the limited numbers did not reach statistical significance ( P = .10) ( Figure 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.